BioCentury | Jan 12, 2021

Novartis gains rights to BeiGene’s PD-1 in North America, Europe and Japan for $650M up front

...its rights to tislelizumab following the company’s acquisition by Bristol Myers Squibb Co. (NYSE:BMY). Virginia Li tislelizumab (BGB-A317) BeiGene...
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...chromosome ten BioCentury Staff PCV-15 (V114) Contepo, fosfomycin (Zolyd, ZTI-01) Relumina (relugolix, TAK-385) ABI-M201 ABI-M301 ipatasertib (GDC-0068, RG7440) belantamab mafodotin, J6M0-mcMMAF (2857916, GSK2857916) tislelizumab (BGB-A317) Dupixent...
BioCentury | Apr 14, 2020
Product Development

April 13 Quick Takes: AZ’s Phase III of Tagrisso unblinded early; plus BeiGene’s tislelizumab and Fennec’s Pedmark

...tislelizumab plus chemotherapy met the primary endpoint of improving progression-free survival in the Phase III BGB-A317-304...
BioCentury | Jan 22, 2020
Clinical News

BeiGene gearing up for PD-1 competition with Merck, Innovent in 1L squamous NSCLC in China

...reached a pre-specified threshold for improving progression-free survival, the primary endpoint in the Phase III BGB-A317-307...
...death 1; PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Sandi Wong, Assistant Editor tislelizumab (BGB-A317) BeiGene...
BioCentury | Jan 7, 2020
Company News

BeiGene looks to carve out niche in China for tislelizumab

...for bladder cancer. Targets: PD-1 (PDCD1; CD279) - Programmed cell death 1 Hongjiang Li, Staff Writer tislelizumab (BGB-A317) BeiGene...
BioCentury | Jan 1, 2020
Company News

Fewer FDA approvals in 2019, but a basket of firsts

...cyd-tdv, ChimeriVax-Dengue) Recombinant Ebola virus vaccine (Ad5-EBOV) Rozlytrek, entrectinib (RG6268, rxdx-101) Vitrakvi, larotrectinib (LOXO-101) Zynteglo (LentiGlobin BB305 gene therapy) tislelizumab (BGB-A317) Zejula...
BioCentury | Dec 31, 2019
Company News

Dec. 31 Company Quick Takes: A first for BeiGene; plus MorphoSys, Junshi-CSPC, Acceleron-Fulcrum and Solasia-EditForce

...upfront payment and is eligible for milestones; specific terms were not disclosed. BioCentury Staff Tuoyi, toripalimab (JS001) tislelizumab (BGB-A317) Solasia...
BioCentury | Nov 14, 2019
Company News

Nov. 13 Company Quick Takes: FDA panel rebuffs Jardiance; plus Nucala, Cellular Biomedicine, BeiGene, Autolus and Noile-Immune

...Chemokine CC motif ligand 19; IL-7 - Interleukin-7; SGLT2 - Sodium-glucose cotransporter 2 BioCentury Staff tislelizumab (BGB-A317) Jardiance...
BioCentury | Sep 9, 2019
Company News

BeiGene pushes back on short seller report

...rights to the cancer drugs from Celgene in return for licensing its PD-1 inhibitor tislelizumab (BGB-A317...
BioCentury | Aug 23, 2019
Company News

BeiGene's first U.S. NDA tests global development strategy

...27. BeiGene is also running both China and global trials for its PD-1 inhibitor tislelizumab (BGB-A317...
...Burton's tyrosine kinase; PD-1 (PDCD1; CD279) - Programmed cell death 1 Hongjiang Li, Staff Writer tislelizumab (BGB-A317) zanubrutinib...
Items per page:
1 - 10 of 64